Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2401766455', 'doi': 'https://doi.org/10.5980/jpnjurol1928.79.1_11', 'title': 'ENHANCEMENT OF CYTOTOXICITY OF ANTICANCER DRUGS BY VERAPAMIL', 'display_name': 'ENHANCEMENT OF CYTOTOXICITY OF ANTICANCER DRUGS BY VERAPAMIL', 'publication_year': 1988, 'publication_date': '1988-01-01', 'ids': {'openalex': 'https://openalex.org/W2401766455', 'doi': 'https://doi.org/10.5980/jpnjurol1928.79.1_11', 'mag': '2401766455', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/3398369'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.5980/jpnjurol1928.79.1_11', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpnjurol1928/79/1/79_1_11/_pdf', 'source': {'id': 'https://openalex.org/S2752698192', 'display_name': 'The Japanese Journal of Urology', 'issn_l': '0021-5287', 'issn': ['0021-5287', '1884-7110'], 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313616', 'host_organization_name': 'Japanese Dermatological Association', 'host_organization_lineage': ['https://openalex.org/P4310313616'], 'host_organization_lineage_names': ['Japanese Dermatological Association'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://www.jstage.jst.go.jp/article/jpnjurol1928/79/1/79_1_11/_pdf', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5026392622', 'display_name': 'Yoshihiro Watanabe', 'orcid': 'https://orcid.org/0000-0002-5756-0530'}, 'institutions': [{'id': 'https://openalex.org/I43777268', 'display_name': 'Nagasaki University', 'ror': 'https://ror.org/058h74p94', 'country_code': 'JP', 'type': 'education', 'lineage': ['https://openalex.org/I43777268']}], 'countries': ['JP'], 'is_corresponding': True, 'raw_author_name': 'Yoshihiro Watanabe', 'raw_affiliation_strings': ['Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan'], 'affiliations': [{'raw_affiliation_string': 'Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan', 'institution_ids': ['https://openalex.org/I43777268']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5026392622'], 'corresponding_institution_ids': ['https://openalex.org/I43777268'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 53}, 'biblio': {'volume': '79', 'issue': '1', 'first_page': '11', 'last_page': '19'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10570', 'display_name': 'Mechanisms of Multidrug Resistance in Cancer', 'score': 0.9987, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10570', 'display_name': 'Mechanisms of Multidrug Resistance in Cancer', 'score': 0.9987, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11845', 'display_name': 'DNA Topoisomerases: Structure, Function, and Inhibition', 'score': 0.9955, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10375', 'display_name': 'Drug Metabolism and Pharmacogenomics', 'score': 0.9912, 'subfield': {'id': 'https://openalex.org/subfields/3004', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/30', 'display_name': 'Pharmacology, Toxicology and Pharmaceutics'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/thymidine', 'display_name': 'Thymidine', 'score': 0.63536364}, {'id': 'https://openalex.org/keywords/anticancer-drugs', 'display_name': 'Anticancer Drugs', 'score': 0.529209}, {'id': 'https://openalex.org/keywords/drug-metabolism', 'display_name': 'Drug Metabolism', 'score': 0.513397}, {'id': 'https://openalex.org/keywords/ic50', 'display_name': 'IC50', 'score': 0.4273638}], 'concepts': [{'id': 'https://openalex.org/C2777022698', 'wikidata': 'https://www.wikidata.org/wiki/Q410291', 'display_name': 'Verapamil', 'level': 3, 'score': 0.99670804}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.6433518}, {'id': 'https://openalex.org/C2777108182', 'wikidata': 'https://www.wikidata.org/wiki/Q422464', 'display_name': 'Thymidine', 'level': 3, 'score': 0.63536364}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.6228951}, {'id': 'https://openalex.org/C109316439', 'wikidata': 'https://www.wikidata.org/wiki/Q246181', 'display_name': 'Cytotoxicity', 'level': 3, 'score': 0.5093771}, {'id': 'https://openalex.org/C2777752497', 'wikidata': 'https://www.wikidata.org/wiki/Q286779', 'display_name': 'IC50', 'level': 3, 'score': 0.4273638}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.28957278}, {'id': 'https://openalex.org/C519063684', 'wikidata': 'https://www.wikidata.org/wiki/Q706', 'display_name': 'Calcium', 'level': 2, 'score': 0.27590734}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.2645656}, {'id': 'https://openalex.org/C202751555', 'wikidata': 'https://www.wikidata.org/wiki/Q221681', 'display_name': 'In vitro', 'level': 2, 'score': 0.2219418}, {'id': 'https://openalex.org/C178790620', 'wikidata': 'https://www.wikidata.org/wiki/Q11351', 'display_name': 'Organic chemistry', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D002292', 'descriptor_name': 'Carcinoma, Renal Cell', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': True}, {'descriptor_ui': 'D007680', 'descriptor_name': 'Kidney Neoplasms', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': True}, {'descriptor_ui': 'D014700', 'descriptor_name': 'Verapamil', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002292', 'descriptor_name': 'Carcinoma, Renal Cell', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D002945', 'descriptor_name': 'Cisplatin', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D002945', 'descriptor_name': 'Cisplatin', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004317', 'descriptor_name': 'Doxorubicin', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D004317', 'descriptor_name': 'Doxorubicin', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004354', 'descriptor_name': 'Drug Screening Assays, Antitumor', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004357', 'descriptor_name': 'Drug Synergism', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007680', 'descriptor_name': 'Kidney Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014407', 'descriptor_name': 'Tumor Cells, Cultured', 'qualifier_ui': 'Q000187', 'qualifier_name': 'drug effects', 'is_major_topic': False}, {'descriptor_ui': 'D014407', 'descriptor_name': 'Tumor Cells, Cultured', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014700', 'descriptor_name': 'Verapamil', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D014750', 'descriptor_name': 'Vincristine', 'qualifier_ui': 'Q000494', 'qualifier_name': 'pharmacology', 'is_major_topic': False}, {'descriptor_ui': 'D014750', 'descriptor_name': 'Vincristine', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.5980/jpnjurol1928.79.1_11', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpnjurol1928/79/1/79_1_11/_pdf', 'source': {'id': 'https://openalex.org/S2752698192', 'display_name': 'The Japanese Journal of Urology', 'issn_l': '0021-5287', 'issn': ['0021-5287', '1884-7110'], 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313616', 'host_organization_name': 'Japanese Dermatological Association', 'host_organization_lineage': ['https://openalex.org/P4310313616'], 'host_organization_lineage_names': ['Japanese Dermatological Association'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/3398369', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.5980/jpnjurol1928.79.1_11', 'pdf_url': 'https://www.jstage.jst.go.jp/article/jpnjurol1928/79/1/79_1_11/_pdf', 'source': {'id': 'https://openalex.org/S2752698192', 'display_name': 'The Japanese Journal of Urology', 'issn_l': '0021-5287', 'issn': ['0021-5287', '1884-7110'], 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4310313616', 'host_organization_name': 'Japanese Dermatological Association', 'host_organization_lineage': ['https://openalex.org/P4310313616'], 'host_organization_lineage_names': ['Japanese Dermatological Association'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being', 'score': 0.75}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 18, 'referenced_works': ['https://openalex.org/W1545285984', 'https://openalex.org/W1606300676', 'https://openalex.org/W1979609083', 'https://openalex.org/W1982055969', 'https://openalex.org/W1989502449', 'https://openalex.org/W2012306261', 'https://openalex.org/W2034862041', 'https://openalex.org/W2108877577', 'https://openalex.org/W2142554300', 'https://openalex.org/W2162807162', 'https://openalex.org/W2395142420', 'https://openalex.org/W2397886985', 'https://openalex.org/W2400782088', 'https://openalex.org/W2411396084', 'https://openalex.org/W2415920076', 'https://openalex.org/W2416846915', 'https://openalex.org/W2432869850', 'https://openalex.org/W2469141838'], 'related_works': ['https://openalex.org/W3146021464', 'https://openalex.org/W2989856591', 'https://openalex.org/W2423534966', 'https://openalex.org/W2401766455', 'https://openalex.org/W2391749367', 'https://openalex.org/W2316957203', 'https://openalex.org/W2065043911', 'https://openalex.org/W2064263988', 'https://openalex.org/W2004105127', 'https://openalex.org/W1989502449'], 'abstract_inverted_index': {'当教室で樹立した人培養腎癌細胞株': [0], '(NUR)': [1], 'および人正常腎細胞': [2], '(PHK)': [3], 'を用い,': [4], 'ビンクリスチン': [5], '(VCR),': [6], 'アドリアマイシン': [7], '(ADM),': [8], 'シスプラチン': [9], '(CDDP)': [10], 'に対する': [11], 'verapamil': [12, 23, 25, 27, 47, 56, 65, 70, 83, 92], 'の効果増強作用について検討した.': [13], '殺細胞効果については,': [14], '細胞の増殖曲線,': [15], '3H-thymidine': [16, 31, 36, 78], 'incorporation': [17, 32, 37, 79], '法で検討した.': [18], 'また細胞内における3H-VCR,': [19], '3H-daunomycin': [20, 61, 72, 90], 'の取り込みを経時的に測定し,': [21], '取り込みおよび放出に対する': [22], 'の影響をみた.': [24], 'の濃度は細胞毒性を示さない1.0μg/mlとした.': [26], 'は': [28], 'NURcell': [29], 'の増殖曲線,': [30], 'のいずれにおいてもADM,': [33], 'VCR,': [34], 'CDDPの殺細胞効果を増強させ,': [35], 'の抑制でみるとIC50': [38], '(drug': [39], 'concentration': [40], 'for': [41], '50%': [42], 'inhibition)': [43], 'は各々制癌剤単独で0.095,': [44], '4.81,': [45], '1.01μg/mlであったものが,': [46], '1.0μg/mlの併用で,': [48], '0.039,': [49], '1.29,': [50], '0.508μg/mlとなった.': [51], 'またNUR': [52], 'cell': [53, 63, 76, 88], 'に対し,': [54], 'ADMの効果増強を生じる': [55], 'の最小濃度は,': [57], '約0.1μg/mlであり,': [58], 'その増強効果は濃度依存性に高められた.': [59], '3H-VCR,': [60], 'のNUR': [62], 'への取り込みは': [64], 'によって,': [66], 'いずれも増加した.': [67], 'しかし細胞外放出に対しては,': [68], '3H-VCRは': [69], 'によって抑制される傾向を示したが,': [71], 'については,': [73], 'その影響を認めなかった.': [74], 'PHK': [75, 87], 'についても': [77], 'によってVCR,': [80], 'ADM,': [81], 'CDDPに対する': [82], 'の影響を検討したが,': [84], 'いずれも軽度であった.': [85], 'また,': [86], 'への3H-VCR,': [89], 'の取り込みに対する': [91], 'の影響も極軽度であった.': [93]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2401766455', 'counts_by_year': [], 'updated_date': '2024-09-19T06:00:58.051122', 'created_date': '2016-06-24'}